In Brief: Nimodipine Oral Solution (Nymalize) ......................................................... p 68

Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints
or call customer service at: 800-211-2769
IN BRIEF

Nimodipine Oral Solution (Nymalize)

The FDA has approved a new oral solution of the calcium channel blocker nimodipine (Nymalize – Arbor) to reduce the severity of neurological deficits associated with vasospasm after subarachnoid hemorrhage from a ruptured intracranial aneurysm. An older formulation of nimodipine has been available for such use for many years.1

Since 1988, nimodipine has been available only in liquid-filled gel capsules (Nimotop, and generics) that a conscious patient could swallow intact. For unconscious patients, the package insert included instructions for use of a needle and syringe to aspirate the liquid from the capsules and inject it into a feeding tube. However, some healthcare providers mistakenly injected the nimodipine liquid into IV tubing instead; IV nimodipine can cause severe hypotension, cardiac arrest and death. In 2006, the FDA added a boxed warning to the labeling regarding the dangers of giving oral nimodipine intravenously, but errors continued to occur. In 2010, the FDA warned again that nimodipine should only be administered orally or through a nasogastric or gastric feeding tube.2

Nymalize, a 60 mg/20 mL solution, can be administered orally or through a nasogastric or gastric feeding tube. Use of the oral syringe supplied with the drug for administration through a feeding tube should prevent erroneous IV injection. No new clinical trials were required for approval of Nymalize.
